GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more
GeoVax Labs Inc (GOVX) - Net Assets
Latest net assets as of September 2025: $4.91 Million USD
Based on the latest financial reports, GeoVax Labs Inc (GOVX) has net assets worth $4.91 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.73 Million) and total liabilities ($1.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.91 Million |
| % of Total Assets | 72.9% |
| Annual Growth Rate | 1.77% |
| 5-Year Change | -47.24% |
| 10-Year Change | 319.1% |
| Growth Volatility | 409.55 |
GeoVax Labs Inc - Net Assets Trend (1996–2024)
This chart illustrates how GeoVax Labs Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GeoVax Labs Inc (1996–2024)
The table below shows the annual net assets of GeoVax Labs Inc from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.05 Million | -12.40% |
| 2023-12-31 | $5.76 Million | -78.33% |
| 2022-12-31 | $26.60 Million | +509.81% |
| 2021-12-31 | $4.36 Million | -54.42% |
| 2020-12-31 | $9.57 Million | +707.73% |
| 2019-12-31 | $-1.57 Million | -54.07% |
| 2018-12-31 | $-1.02 Million | -218.32% |
| 2017-12-31 | $-321.06K | -233.57% |
| 2016-12-31 | $240.37K | -80.05% |
| 2015-12-31 | $1.20 Million | +5.10% |
| 2014-12-31 | $1.15 Million | -54.65% |
| 2013-12-31 | $2.53 Million | +119.58% |
| 2012-12-31 | $1.15 Million | +63.58% |
| 2011-12-31 | $703.61K | -61.68% |
| 2010-12-31 | $1.84 Million | -50.96% |
| 2009-12-31 | $3.74 Million | +38.17% |
| 2008-12-31 | $2.71 Million | +2.34% |
| 2007-12-31 | $2.65 Million | +20.18% |
| 2006-12-31 | $2.20 Million | +138.55% |
| 2005-12-31 | $-5.72 Million | -15.55% |
| 2004-12-31 | $-4.95 Million | -29.58% |
| 2003-12-31 | $-3.82 Million | -497.01% |
| 2002-12-31 | $-639.39K | -131.21% |
| 2001-12-31 | $2.05 Million | -80.53% |
| 2000-12-31 | $10.52 Million | +1804.77% |
| 1999-12-31 | $552.34K | -80.86% |
| 1998-12-31 | $2.89 Million | -49.16% |
| 1997-12-31 | $5.68 Million | +83.50% |
| 1996-12-31 | $3.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to GeoVax Labs Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12935606159914200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.54K | 0.00% |
| Other Components | $134.40 Trillion | 2662.25% |
| Total Equity | $5.05 Trillion | 100.00% |
GeoVax Labs Inc Competitors by Market Cap
The table below lists competitors of GeoVax Labs Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TREVI - Finanziaria Industriale S.p.A.
LSE:0G91
|
$1.99 Million |
|
SPACEANDPEOPLE LS-1
F:RWK0
|
$2.00 Million |
|
AVI Japan Opportunity Trust PLC
LSE:AJOT
|
$2.00 Million |
|
Abpro Holdings, Inc.
NYSE:ABP
|
$2.00 Million |
|
TV Thunder Public Company Limited
BK:TVT
|
$1.99 Million |
|
Intersport Polska S.A.
WAR:IPO
|
$1.99 Million |
|
Commcenter S.A.
MC:CMM
|
$1.99 Million |
|
bioAffinity Technologies Inc. Warrant
NASDAQ:BIAFW
|
$1.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeoVax Labs Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,763,338 to 5,048,535,000,000, a change of 5,048,529,236,662 (87597313.2%).
- Net loss of 24,992,296 reduced equity.
- New share issuances of 21,398,383 increased equity.
- Other factors increased equity by 5,048,532,830,575.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.99 Million | -0.0% |
| Share Issuances | $21.40 Million | +0.0% |
| Other Changes | $5.05 Trillion | +100.0% |
| Total Change | $- | 87597313.17% |
Book Value vs Market Value Analysis
This analysis compares GeoVax Labs Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $77322500.00 | $1.68 | x |
| 1997-12-31 | $141889875.00 | $1.68 | x |
| 1998-12-31 | $72130700.00 | $1.68 | x |
| 1999-12-31 | $13808600.00 | $1.68 | x |
| 2000-12-31 | $263021600.00 | $1.68 | x |
| 2001-12-31 | $51222275.00 | $1.68 | x |
| 2002-12-31 | $-15984825.00 | $1.68 | x |
| 2003-12-31 | $-95430300.00 | $1.68 | x |
| 2004-12-31 | $-123654625.00 | $1.68 | x |
| 2005-12-31 | $-142879800.00 | $1.68 | x |
| 2006-12-31 | $55080400.00 | $1.68 | x |
| 2007-12-31 | $66196650.00 | $1.68 | x |
| 2008-12-31 | $67745475.00 | $1.68 | x |
| 2009-12-31 | $93605800.00 | $1.68 | x |
| 2010-12-31 | $36724520.00 | $1.68 | x |
| 2011-12-31 | $14072140.00 | $1.68 | x |
| 2012-12-31 | $19182250.00 | $1.68 | x |
| 2013-12-31 | $36103242.86 | $1.68 | x |
| 2014-12-31 | $12735277.78 | $1.68 | x |
| 2015-12-31 | $10950936.36 | $1.68 | x |
| 2016-12-31 | $1716928.57 | $1.68 | x |
| 2017-12-31 | $-1395900.00 | $1.68 | x |
| 2018-12-31 | $-1858181.82 | $1.68 | x |
| 2019-12-31 | $-15745560.00 | $1.68 | x |
| 2020-12-31 | $103.72 | $1.68 | x |
| 2021-12-31 | $10.73 | $1.68 | x |
| 2022-12-31 | $23.51 | $1.68 | x |
| 2023-12-31 | $3.17 | $1.68 | x |
| 2024-12-31 | $973298.25 | $1.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeoVax Labs Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -631.98%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 0.00x
- Recent ROE (-0.00%) is above the historical average (-188.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 1185.58% | 39031.23% | 0.03x | 1.10x | $36.36 Million |
| 1997 | -70.27% | -146.08% | 0.38x | 1.28x | $-4.56 Million |
| 1998 | -212.52% | -114.23% | 0.80x | 2.33x | $-6.42 Million |
| 1999 | -1684.87% | -408.34% | 0.68x | 6.11x | $-9.36 Million |
| 2000 | -83.81% | -1025.47% | 0.08x | 1.06x | $-9.87 Million |
| 2001 | -646.81% | -505.78% | 0.67x | 1.91x | $-13.46 Million |
| 2002 | 0.00% | -342.96% | 0.49x | 0.00x | $-554.20K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.70 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.71 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-837.01K |
| 2006 | -26.51% | -68.49% | 0.36x | 1.09x | $-804.49K |
| 2007 | -160.20% | -1789.76% | 0.07x | 1.23x | $-4.51 Million |
| 2008 | -137.58% | -128.11% | 0.95x | 1.13x | $-4.00 Million |
| 2009 | -87.71% | -89.53% | 0.85x | 1.15x | $-3.66 Million |
| 2010 | -149.62% | -52.98% | 2.20x | 1.28x | $-2.93 Million |
| 2011 | -333.54% | -47.90% | 2.98x | 2.34x | $-2.42 Million |
| 2012 | -185.50% | -80.35% | 1.80x | 1.28x | $-2.25 Million |
| 2013 | -90.41% | -94.51% | 0.85x | 1.12x | $-2.54 Million |
| 2014 | -238.49% | -309.59% | 0.66x | 1.16x | $-2.85 Million |
| 2015 | -223.25% | -628.22% | 0.32x | 1.11x | $-2.81 Million |
| 2016 | -1361.11% | -394.70% | 1.36x | 2.54x | $-3.30 Million |
| 2017 | 0.00% | -201.82% | 2.19x | 0.00x | $-2.14 Million |
| 2018 | 0.00% | -265.84% | 1.50x | 0.00x | $-2.46 Million |
| 2019 | 0.00% | -201.60% | 2.51x | 0.00x | $-2.21 Million |
| 2020 | -30.71% | -161.18% | 0.18x | 1.09x | $-3.90 Million |
| 2021 | -424.84% | -4813.37% | 0.03x | 2.70x | $-18.97 Million |
| 2022 | -52.69% | -17301.93% | 0.00x | 1.18x | $-16.67 Million |
| 2023 | -450.55% | 0.00% | 0.00x | 1.61x | $-26.54 Million |
| 2024 | 0.00% | -631.98% | 0.48x | 0.00x | $-504.88 Billion |
Industry Comparison
This section compares GeoVax Labs Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeoVax Labs Inc (GOVX) | $4.91 Million | 1185.58% | 0.37x | $1.99 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |